The estimated Net Worth of Kevin R Sayer is at least 198 百万$ dollars as of 8 April 2024. Mr. Sayer owns over 49,633 units of Dexcom Inc stock worth over 19,438,154$ and over the last 17 years he sold DXCM stock worth over 168,347,330$. In addition, he makes 10,279,400$ as Chairman of the Board、 President、 Chief Executive Officer at Dexcom Inc.
Kevin has made over 77 trades of the Dexcom Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 49,633 units of DXCM stock worth 6,864,244$ on 8 April 2024.
The largest trade he's ever made was selling 81,007 units of Dexcom Inc stock on 12 March 2024 worth over 10,803,094$. On average, Kevin trades about 9,734 units every 38 days since 2007. As of 8 April 2024 he still owns at least 283,893 units of Dexcom Inc stock.
You can see the complete history of Mr. Sayer stock trades at the bottom of the page.
Kevin R. Sayer serves as Chairman of the Board, President, Chief Executive Officer of the Company. He has served on our Board since November 2007, as our President and Chief Executive Officer ("CEO") since January 2015 and as our Chairman of the Board of Directors ("Chairman") since July 2018. Mr. Sayer has been our President since 2011, and from January 2013 until January 2015, Mr. Sayer also served as our Chief Operating Officer. From April 2007 to December 2010, Mr. Sayer served as Chief Financial Officer of Biosensors International Group, Ltd. ("Biosensors"), a medical technology company developing, manufacturing and commercializing medical devices used in interventional cardiology and critical care procedures. Prior to joining Biosensors, from May 2005 to April 2007, Mr. Sayer served as an independent healthcare and medical technology industry consultant. From March 2004 to May 2005, Mr. Sayer was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a company offering clinical reference laboratory services. From August 2002 to March 2004, Mr. Sayer worked as an independent healthcare and medical technology industry consultant. Mr. Sayer served as Chief Financial Officer of MiniMed, Inc. from May 1994 until it was acquired by Medtronic, Inc. in August 2001. Mr. Sayer served as Vice President and General Manager of Medtronic MiniMed after the acquisition until August 2002. Mr. Sayer is a Certified Public Accountant (inactive) and received his Master's Degree in Accounting and Information Systems concurrently with a B.A., both from Brigham Young University. As CEO, Mr. Sayer has direct responsibility for our strategy and operations.
As the Chairman of the Board、 President、 Chief Executive Officer of Dexcom Inc, the total compensation of Kevin Sayer at Dexcom Inc is 10,279,400$. There are no executives at Dexcom Inc getting paid more.
Kevin Sayer is 62, he's been the Chairman of the Board、 President、 Chief Executive Officer of Dexcom Inc since 2018. There are 7 older and 21 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Kevin's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 19 years, insiders at Dexcom Inc have traded over 724,717,982$ worth of Dexcom Inc stock and bought 165,450 units worth 3,489,100$ . The most active insiders traders include Sean Carney、Kim D Blickenstaff、Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of 892,438$. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth 29,458$.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: